See more : Sunfar Computer Co., Ltd (6154.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of PMV Pharmaceuticals, Inc. (PMVP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PMV Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wuhan Zhongyuan Huadian Science & Technology Co.,Ltd. (300018.SZ) Income Statement Analysis – Financial Results
- Just Eat Takeaway.com N.V. (TKWY.AS) Income Statement Analysis – Financial Results
- Alpha Services and Holdings S.A. (ALPHA.AT) Income Statement Analysis – Financial Results
- Dye & Durham Limited (DND.TO) Income Statement Analysis – Financial Results
- ROHM Co., Ltd. (ROHCY) Income Statement Analysis – Financial Results
PMV Pharmaceuticals, Inc. (PMVP)
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| Gross Profit | -1.26M | -650.00K | -1.28M | -318.00K | -388.00K | -338.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.89M | 51.99M | 36.49M | 23.93M | 20.76M | 13.85M |
| General & Administrative | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Other Expenses | 0.00 | 87.00K | 21.00K | -143.00K | -8.00K | 16.00K |
| Operating Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Cost & Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Interest Income | 11.17M | 3.63M | 449.00K | 651.00K | 1.30M | 1.34M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| EBITDA | -78.88M | -76.73M | -57.99M | -34.62M | -26.25M | -18.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.13M | -77.04M | -58.29M | -34.94M | -26.64M | -18.89M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.17M | 3.71M | 470.00K | 508.00K | 1.29M | 1.36M |
| Income Before Tax | -68.96M | -73.33M | -57.82M | -34.43M | -25.34M | -17.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | -9.00K | 23.00K | 6.00K | 8.00K | 3.00K |
| Net Income | -68.96M | -73.32M | -57.85M | -34.44M | -25.35M | -17.54M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| EPS Diluted | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| Weighted Avg Shares Out | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
| Weighted Avg Shares Out (Dil) | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
CRANBURY, N.J., April 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today presented preclinical data on PC14586, the Company's first-in-class, tumor-agnostic,...
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that the company will present at the American...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
CRANBURY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the fourth quarter and full...
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Guillermina (Gigi) Lozano, Ph.D., to...
3 Net-Net Working Capital Stocks
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassessed the share prices to near or above the liquidation value.
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced dosing of the first patient in its Phase...
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the third quarter ended September...
Source: https://incomestatements.info
Category: Stock Reports